Login to Your Account

Lawmakers push to pin drug prices to must-pass user fee agreements

By Mari Serebrov
Regulatory Editor

Tuesday, May 16, 2017

This year’s renewal of the FDA UFAs for drugs and devices is pitting industry hopes for a “clean” bill and timely action against some U.S. lawmakers’ pledges to put teeth to their sound bites on drug prices.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription